Regencell Bioscience Debt

RGC Stock  USD 6.32  0.33  5.51%   
Regencell Bioscience holds a debt-to-equity ratio of 0.069. At present, Regencell Bioscience's Interest Debt Per Share is projected to increase slightly based on the last few years of reporting. With a high degree of financial leverage come high-interest payments, which usually reduce Regencell Bioscience's Earnings Per Share (EPS).

Asset vs Debt

Equity vs Debt

Regencell Bioscience's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Regencell Bioscience's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Regencell Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Regencell Bioscience's stakeholders.
For most companies, including Regencell Bioscience, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Regencell Bioscience Holdings, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Regencell Bioscience's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book
10.0066
Book Value
0.632
Return On Assets
(0.28)
Return On Equity
(0.43)
As of November 30, 2024, Total Current Liabilities is expected to decline to about 183.9 K. In addition to that, Liabilities And Stockholders Equity is expected to decline to about 8 M
  
Check out the analysis of Regencell Bioscience Fundamentals Over Time.

Regencell Bioscience Bond Ratings

Regencell Bioscience Holdings financial ratings play a critical role in determining how much Regencell Bioscience have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Regencell Bioscience's borrowing costs.
Piotroski F Score
4
PoorView
Beneish M Score
(4.54)
Unlikely ManipulatorView

Regencell Bioscience Debt to Cash Allocation

As Regencell Bioscience Holdings follows its natural business cycle, the capital allocation decisions will not magically go away. Regencell Bioscience's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
Regencell Bioscience Holdings has 85.74 K in debt with debt to equity (D/E) ratio of 0.07, which may show that the company is not taking advantage of profits from borrowing. Regencell Bioscience has a current ratio of 13.66, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Regencell to invest in growth at high rates of return.

Regencell Bioscience Total Assets Over Time

Regencell Bioscience Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Regencell Bioscience uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Regencell Bioscience Debt Ratio

    
  71.0   
It looks as if most of the Regencell Bioscience's assets are financed through debt. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Regencell Bioscience's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Regencell Bioscience, which in turn will lower the firm's financial flexibility.

Regencell Bioscience Corporate Bonds Issued

Most Regencell bonds can be classified according to their maturity, which is the date when Regencell Bioscience Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Regencell Short Long Term Debt Total

Short Long Term Debt Total

81,453.95

At present, Regencell Bioscience's Short and Long Term Debt Total is projected to decrease significantly based on the last few years of reporting.

Understaning Regencell Bioscience Use of Financial Leverage

Regencell Bioscience's financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures Regencell Bioscience's total debt position, including all outstanding debt obligations, and compares it with Regencell Bioscience's equity. Financial leverage can amplify the potential profits to Regencell Bioscience's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if Regencell Bioscience is unable to cover its debt costs.
Last ReportedProjected for Next Year
Short and Long Term Debt Total85.7 K81.5 K
Net Debt-2.9 M-2.7 M
Short Term Debt59.8 K56.8 K
Short and Long Term Debt4.2 M3.2 M
Net Debt To EBITDA 0.79  4.56 
Debt To Equity(3.18)(3.34)
Interest Debt Per Share 13.62  14.30 
Debt To Assets 0.75  0.71 
Long Term Debt To Capitalization 1.42  0.74 
Total Debt To Capitalization 1.41  0.74 
Debt Equity Ratio(3.18)(3.34)
Debt Ratio 0.75  0.71 
Cash Flow To Debt Ratio 0.20  0.19 
Please read more on our technical analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:
Check out the analysis of Regencell Bioscience Fundamentals Over Time.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.33)
Return On Assets
(0.28)
Return On Equity
(0.43)
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.